TRBC1 and leukemia: Interestingly, Maciocia et al. [106] developed a new strategy for the CAR-T therapy to treat T-cell malignancies and demonstrated that anti-T cell receptor-chain constant domain 1 (TRBC1) CAR-T recognized and killed normal and malignant TRBC1+, but not TRBC2+, T cells in mouse model of leukemia.